Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.

Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.
复制标题

DOI:
10.1039/c5nr08691d
复制
发表时间:
2016-07-07
期刊:
影响因子:
6.7
通讯作者:
Hasan T
Hasan T
中科院分区:
材料科学2区
文献类型:
--
作者:
Obaid G;Broekgaarden M;Bulin AL;Huang HC;Kuriakose J;Liu J;Hasan T

文献摘要

被引文献

相似文献

随着临床纳米医学在过去二十年的出现,使用纳米技术的光疗进步也不断发展并影响疾病管理。由于分子光激活过程的独特特征,光子纳米医学 (PNM) 作为癌症和非癌症病理的个性化、图像引导治疗方法具有重大前景。光动力疗法 (PDT) 等先进光化学疗法和成像模式与先进纳米技术的融合,使得 Visudyne® 等基本 PNM 制剂不断发展成为先进的前瞻性平台,整合了治疗诊断学(治疗学和诊断学)、分子选择性、协同治疗药物的时空控制释放以及受监管的持续药物剂量。考虑到这些集成平台的预期目标被证明是现实的,本综述将讨论 PNM 作为纳米技术与 PDT 的临床前和临床融合多年来如何发展。令人鼓舞的研究强调光化学和纳米治疗学之间的强大协同作用,除了人们日益认识到这些多方面治疗诊断纳米平台的价值之外,将有助于推动 PNM 制剂作为医疗设备中的必要工具进入主流肿瘤临床实践。
As clinical nanomedicine has emerged over the past two decades, phototherapeutic advancements using nanotechnology have also evolved and impacted disease management. Because of unique features attributable to the light activation process of molecules, photonanomedicine (PNM) holds significant promise as a personalized, image-guided therapeutic approach for cancer and non-cancer pathologies. The convergence of advanced photochemical therapies such as photodynamic therapy (PDT) and imaging modalities with sophisticated nanotechnologies is enabling the ongoing evolution of fundamental PNM formulations, such as Visudyne®, into progressive forward-looking platforms that integrate theranostics (therapeutics and diagnostics), molecular selectivity, the spatiotemporally controlled release of synergistic therapeutics, along with regulated, sustained drug dosing. Considering that the envisioned goal of these integrated platforms is proving to be realistic, this review will discuss how PNM has evolved over the years as a preclinical and clinical amalgamation of nanotechnology with PDT. The encouraging investigations that emphasize the potent synergy between photochemistry and nanotherapeutics, in addition to the growing realization of the value of these multi-faceted theranostic nanoplatforms, will assist in driving PNM formulations into mainstream oncological clinical practice as a necessary tool in the medical armamentarium.